Navigation Links
UC Davis team refines cancer treatments to reduce potential nerve damage
Date:12/15/2008

(SACRAMENTO, Calif.) While radiation treatments deliver precise doses of high-energy X-rays to stop cancer cells from spreading or to shrink tumors, oncologists have become increasingly concerned about inadvertent exposures during head and neck cancer treatments to nerves responsible for upper body mobility. To reduce the possibility of permanent nerve damage, UC Davis Cancer Center researchers have taken the lead in establishing new treatment guidelines for physicians nationwide.

The team, led by Allen Chen, assistant professor of radiation oncology, noticed a trend following treatment for cancers of the tonsil, tongue, throat, and other head and neck organs: A number of patients reported ongoing weakness and sensation problems in their necks, shoulders and upper arms. Chen recognized that these symptoms could be attributed to injury of the brachial plexus nerves, which begin at the back of the neck and extend behind the clavicle and down to the hand. Specific standards for delivering radiation treatments and avoiding this critical body structure, however, did not exist.

"Radiation is an essential treatment for most head and neck cancers, and current technologies make it possible for us to successfully target those tumors," said Chen. "Exposure to other tissues is unavoidable and typically not considered serious or long-term. But brachial plexus damage can be permanent and debilitating, so we decided to develop treatment guidelines to reduce radiation exposure to these nerves."

As a result, Chen and his colleagues established step-by-step techniques for identifying the brachial plexus complex using common anatomical "bench posts" that are easily visible with computed tomography scans commonly used for treatment planning. He then designed delivery contours for intensity-modulated radiation therapy treatments to avoid those areas, and tested the guidelines on 10 patients with a variety of head and neck cancers.

Outcomes of the study show that the guidelines, which are published in the December 2008 issue of the International Journal of Radiation Oncology, Biology and Physiology, can be used to evaluate the exact radiation doses delivered to the brachial plexus as well as potentially reduce exposures to levels that meet current medical standards. Patients in the study will continue to be monitored for upper body mobility symptoms and to determine if their radiation treatments were as effective as those delivered prior to the new guidelines.

Chen will next refine the guidelines for patients whose anatomies are distinct due to medical treatments or who may have alternate brachial plexus pathways. For some people, for instance, these nerves begin at a slightly lower or higher point in the neck.

"Not all patients have the same body structures, and we will be adding to the recommendations to account for those differences," Chen said. "Our goals are to lessen the impact of cancer treatments as much as possible, and we are committed to taking a leadership role in making sure that radiation treatments for cancer are as safe, effective and comfortable as possible."


'/>"/>

Contact: Karen Finney
karen.finney@ucdmc.ucdavis.edu
916-734-9064
University of California - Davis - Health System
Source:Eurekalert

Related biology news :

1. UC Davis researchers exploring gene therapy to fight AIDS
2. UC Davis researchers discover Achilles heel in pancreatic cancer
3. UC Davis researchers discover a key to aggressive breast cancer
4. UC Davis chemical ecologist wins major award
5. UC Davis researchers discover new drug target for inflammatory disease
6. UC Davis researchers define characteristics, treatment options for XXYY syndrome
7. UC Davis researcher leads climate-change discovery
8. UC Davis stem researchers demonstrate safety of gene therapy using adult stem cells
9. UC Davis researchers discover how HIV turns food-poisoning into lethal infection
10. UC Davis bird-flu expert calls for changes in early-warning system
11. New tool could unpick complex cancer causes and help sociologists mine Facebook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: